Sodium Iodide 131 Therapeutic Capsule Market Size, Share, Growth, and Industry Analysis, By Type ( 37-7400 MBq/ Capsule, 7400MBq-/ Capsule ), By Application (Thyroid Cancer Treatment, Hyperthyroidism Treatment), Regional Insights and Forecast to 2035

Sodium Iodide 131 Therapeutic Capsule Market Overview

The Global Sodium Iodide 131 Therapeutic Capsule Market size is anticipated to be valued at USD 161.49 million in 2026, with a projected growth to USD 397.38 million by 2035 at a CAGR of 9.8%.

The Sodium Iodide 131 Therapeutic Capsule Market is experiencing steady expansion due to increasing demand for targeted radionuclide therapies, rising thyroid disorder prevalence, and continuous advancements in nuclear medicine infrastructure. Healthcare providers are increasingly adopting radioactive iodine-based treatments because of their effectiveness in thyroid cancer management and hyperthyroidism treatment. The market is supported by improved production capabilities, enhanced capsule safety features, and growing availability of specialized nuclear medicine centers. Approximately 42% of treatment-related demand is influenced by increasing adoption of precise thyroid-focused therapies, which are helping healthcare systems improve patient outcomes while reducing unnecessary exposure to surrounding tissues.

The USA Sodium Iodide 131 Therapeutic Capsule Market is advancing due to strong healthcare infrastructure, increasing adoption of advanced radiopharmaceutical solutions, and rising investments in nuclear medicine facilities. The country continues to strengthen diagnostic and therapeutic capabilities through specialized treatment centers, regulatory support, and research activities focused on radioactive therapies. Around 31% of regional demand is associated with expanding thyroid cancer treatment programs and improved access to targeted therapeutic solutions across hospitals and specialized clinics.

Key Findings

• Market Driver: Rising adoption of targeted radionuclide therapy is accelerating demand, with approximately 42% of market growth influenced by increasing thyroid disorder treatment requirements across specialized healthcare facilities.
• Major Market Restraint: Limited availability of nuclear medicine infrastructure remains a challenge, with around 28% of adoption barriers linked to specialized handling requirements and treatment facility limitations.
• Emerging Trends: Advanced radiopharmaceutical technologies are shaping treatment approaches, with approximately 34% of innovation activity focused on improving capsule safety, precision, and therapeutic effectiveness.
• Regional Leadership: North America leads market development due to advanced healthcare systems and nuclear medicine adoption, accounting for approximately 36% market participation supported by specialized treatment centers.
• Competitive Landscape: Leading companies are expanding production capabilities and strengthening supply networks, with around 25% of strategic activities focused on improving radioactive therapeutic product availability.
• Market Segmentation: The 7400MBq-/ Capsule segment holds approximately 55% share due to higher therapeutic applications, while Thyroid Cancer Treatment represents around 58% demand among supplied applications.
• Recent Development: Manufacturers are increasing research and production capabilities, with approximately 30% of recent initiatives focused on enhancing radioactive iodine treatment efficiency and distribution networks.

Latest Trends

The Sodium Iodide 131 Therapeutic Capsule Market is witnessing increasing adoption of personalized nuclear medicine approaches as healthcare providers focus on improving treatment accuracy and patient-specific therapy planning. The integration of improved manufacturing techniques, radiation safety processes, and quality control systems is supporting broader acceptance of therapeutic capsules. Approximately 34% of technology-focused developments are directed toward enhancing product reliability, reducing handling risks, and improving therapeutic outcomes for thyroid-related conditions.

Another important trend shaping the market is the expansion of nuclear medicine facilities across emerging healthcare regions. Hospitals and specialized treatment centers are investing in advanced radioactive therapy infrastructure to address rising demand for thyroid cancer and hyperthyroidism management. Around 31% of market activities are influenced by healthcare modernization programs, improved radiopharmaceutical accessibility, and increasing collaboration between manufacturers and medical institutions.

Market Dynamics

Driver

"Increasing adoption of targeted thyroid therapies supports market expansion"

The primary driver of the Sodium Iodide 131 Therapeutic Capsule Market is the growing preference for targeted radioactive iodine treatments in thyroid-related healthcare applications. Sodium Iodide 131 therapeutic capsules provide controlled radiation delivery, making them valuable for thyroid cancer treatment and hyperthyroidism treatment. Approximately 42% of healthcare demand is associated with increasing utilization of precise therapeutic approaches that improve treatment effectiveness while supporting better patient management.Expansion of specialized nuclear medicine departments is further strengthening market growth as hospitals improve their capability to provide radioactive therapies. Healthcare providers are investing in radiation safety infrastructure, trained professionals, and advanced treatment facilities to support increasing patient volumes. 

Restraint

"Infrastructure limitations create barriers for wider therapeutic adoption"

The market faces challenges due to the requirement for specialized facilities, regulatory compliance, and trained professionals for radioactive iodine therapy administration. Many healthcare centers in developing regions experience limitations related to infrastructure availability and operational complexity. Approximately 28% of adoption constraints are associated with restricted access to specialized nuclear medicine facilities and radiation handling capabilities.Supply chain management for radioactive therapeutic products also creates operational challenges because production, transportation, and storage require strict safety procedures. Manufacturers must maintain reliable distribution systems while meeting regulatory requirements. Around 22% of market limitations are influenced by logistical complexities related to radioactive material management and controlled healthcare delivery systems.

Opportunity

"Healthcare expansion creates new opportunities for radioactive therapies"

Increasing healthcare investments in emerging economies are creating significant opportunities for Sodium Iodide 131 Therapeutic Capsule adoption. Growing awareness of thyroid disease management and expanding access to specialized medical treatments are encouraging hospitals to develop nuclear medicine capabilities. Approximately 35% of future opportunities are associated with infrastructure development, advanced treatment centers, and improved access to therapeutic radiopharmaceutical products.Technological improvements in capsule manufacturing and treatment planning are also creating opportunities for market participants. Companies are focusing on improving product consistency, safety measures, and distribution efficiency to address evolving healthcare requirements. Around 31% of future growth opportunities are linked to innovation in production processes and expansion of specialized therapeutic applications.

Challenge

"Regulatory complexity influences production and distribution efficiency"

The Sodium Iodide 131 Therapeutic Capsule Market faces challenges related to strict regulatory requirements governing radioactive materials. Manufacturers must maintain high-quality production standards, ensure radiation safety, and comply with regional healthcare regulations. Approximately 27% of operational challenges are connected with regulatory procedures, approval requirements, and controlled distribution practices.Another challenge is maintaining consistent supply availability due to the specialized nature of radioactive isotope production. The market requires coordinated manufacturing, transportation, and healthcare delivery systems to ensure timely availability of therapeutic capsules. Around 24% of supply-related difficulties are influenced by production scheduling, isotope availability, and infrastructure dependencies.

Sodium Iodide 131 Therapeutic Capsule Market Segmentation

By Types

37-7400 MBq/ Capsule: The 37-7400 MBq/ Capsule segment represents an important category within the Sodium Iodide 131 Therapeutic Capsule Market, supporting treatment requirements where controlled radioactive dosage administration is preferred. This segment accounts for approximately 45% market share as healthcare providers utilize lower-dose therapeutic options for selected thyroid-related treatments and patient-specific therapy planning. Increasing adoption of personalized treatment approaches and improved dosage management systems continue supporting demand for this capsule category.Demand for this product type is supported by hospitals and nuclear medicine centers focusing on optimized radiation exposure management and efficient therapeutic procedures. 

7400MBq-/ Capsule: The 7400MBq-/ Capsule segment dominates the Sodium Iodide 131 Therapeutic Capsule Market due to its suitability for advanced therapeutic applications requiring higher radioactive dosage levels. This segment holds approximately 55% market share, driven by increasing utilization in thyroid cancer treatment where stronger therapeutic radiation delivery is required for effective disease management.Higher-dose therapeutic capsules are gaining importance as medical institutions expand specialized radioactive iodine treatment programs. Approximately 38% of demand within this category is influenced by the increasing requirement for efficient treatment solutions, improved patient outcomes, and expanded availability of advanced nuclear medicine facilities.

By Applications

Thyroid Cancer Treatment: Thyroid Cancer Treatment represents the leading application segment in the Sodium Iodide 131 Therapeutic Capsule Market due to increasing adoption of radioactive iodine therapy for targeted cancer management. This application accounts for approximately 58% market share, supported by growing demand for precise treatment methods that minimize damage to surrounding healthy tissues.Healthcare providers are increasingly incorporating Sodium Iodide 131 therapeutic capsules into comprehensive thyroid cancer care programs. Around 41% of application growth is associated with improved treatment protocols, rising availability of specialized oncology centers, and increasing awareness of targeted radionuclide therapies among healthcare professionals.

Hyperthyroidism Treatment: Hyperthyroidism Treatment is another significant application area within the market, driven by the increasing requirement for effective management of thyroid hormone disorders. This segment represents approximately 42% market share as patients and healthcare providers seek reliable therapeutic alternatives for controlling excessive thyroid activity.Expansion of outpatient nuclear medicine services and improved access to therapeutic procedures are supporting demand for Sodium Iodide 131 capsules in hyperthyroidism management. Approximately 33% of application development is influenced by advancements in treatment accessibility, patient monitoring approaches, and healthcare infrastructure improvements.

Sodium Iodide 131 Therapeutic Capsule Market Regional Outlook

North America

North America maintains a leading position in the Sodium Iodide 131 Therapeutic Capsule Market due to advanced healthcare infrastructure, strong nuclear medicine capabilities, and widespread adoption of targeted thyroid therapies. The region accounts for approximately 36% market share, supported by established treatment centers, skilled medical professionals, and increasing demand for radioactive iodine-based therapeutic solutions. The presence of specialized oncology hospitals, advanced radiopharmaceutical distribution networks, and experienced nuclear medicine departments further strengthens regional adoption.The regional market is supported by continuous improvements in healthcare technology, expansion of specialized oncology facilities, and increasing investment in nuclear medicine services. Around 32% of regional demand is influenced by hospitals upgrading therapeutic capabilities and adopting advanced radioactive treatment procedures to improve patient care efficiency.

Europe

Europe represents a significant market for Sodium Iodide 131 Therapeutic Capsules due to developed healthcare systems, strong regulatory frameworks, and increasing adoption of nuclear medicine treatments. The region holds approximately 27% market share as hospitals and specialized treatment facilities continue integrating radioactive iodine therapy into thyroid disease management programs. Countries including Germany, France, the United Kingdom, and Italy are contributing to regional growth through advanced healthcare infrastructure and established nuclear medicine research capabilities.European healthcare providers are focusing on improving treatment accessibility, strengthening radiation safety procedures, and expanding specialized medical facilities. Around 30% of regional activities are associated with healthcare modernization initiatives, advanced therapeutic planning, and increased utilization of radiopharmaceutical solutions across major healthcare networks.

Asia-Pacific

Asia-Pacific is emerging as a rapidly expanding region in the Sodium Iodide 131 Therapeutic Capsule Market due to increasing healthcare investments, rising thyroid disorder cases, and improving availability of nuclear medicine facilities. The region represents approximately 24% market share, supported by expanding healthcare infrastructure and growing adoption of advanced treatment solutions. Countries such as China, Japan, India, and South Korea are witnessing increasing demand due to improvements in hospital facilities and greater access to specialized medical procedures.Countries across Asia-Pacific are increasing investments in specialized hospitals, radiopharmaceutical production capabilities, and medical technology development. Around 35% of regional growth opportunities are connected with healthcare expansion programs, improved treatment accessibility, and increasing awareness regarding radioactive iodine therapies.

Middle East and Africa

The Middle East and Africa region is gradually developing within the Sodium Iodide 131 Therapeutic Capsule Market as healthcare systems improve access to specialized treatment services. The region contributes approximately 8% market share, supported by increasing investments in advanced medical facilities and growing adoption of nuclear medicine applications. Major healthcare hubs in countries such as Saudi Arabia, the United Arab Emirates, and South Africa are improving availability of specialized therapeutic services.Healthcare organizations in the region are focusing on improving diagnostic and therapeutic capabilities through partnerships, infrastructure upgrades, and specialized treatment centers. Around 21% of regional development activities are associated with expanding nuclear medicine access and strengthening healthcare service delivery systems.

Rest of World

Rest of World markets are showing steady growth due to increasing awareness of radioactive iodine therapies and gradual improvements in healthcare infrastructure. The region accounts for approximately 5% market share as medical institutions continue adopting specialized treatment approaches for thyroid-related conditions. Emerging healthcare systems are gradually improving access to radiopharmaceutical products through international supply networks and healthcare partnerships.Growth across these markets is supported by improving healthcare investment, increasing availability of medical technologies, and expansion of international healthcare collaborations. Around 18% of regional opportunities are linked with improving access to therapeutic radiopharmaceutical solutions and strengthening healthcare capabilities.

List of Top Sodium Iodide 131 Therapeutic Capsule Companies

• ANSTO
• PDRadiopharma Inc.
• China Isotope & Radiation Corporation (CIRC)
• International Isotopes Inc
• Curium Pharma
• Jubilant Pharmova
• POLATOM–NCBJ
• NTP Radioisotopes
• Isotope JSC (Rosatom)

Top Two Companies With Highest Market Share

• ANSTO: ANSTO maintains a strong competitive position in the Sodium Iodide 131 Therapeutic Capsule Market through advanced isotope production capabilities, established healthcare partnerships, and extensive experience in nuclear medicine solutions. The company supports global therapeutic supply networks and focuses on maintaining reliable production quality. Approximately 24% of competitive activities associated with leading suppliers are influenced by production expansion, isotope availability improvement, and healthcare collaboration initiatives.
• Curium Pharma: Curium Pharma holds a significant position in the market through its broad radiopharmaceutical portfolio, advanced manufacturing capabilities, and strong distribution network. The company focuses on improving therapeutic isotope accessibility and strengthening nuclear medicine applications across healthcare systems. Around 19% of strategic market activities among major companies are connected with product development, manufacturing optimization, and expansion of radiopharmaceutical services.

Investment Analysis And Opportunities

Investment activity in the Sodium Iodide 131 Therapeutic Capsule Market is increasing as manufacturers focus on improving isotope production efficiency, strengthening quality control systems, and expanding therapeutic radiopharmaceutical capabilities. Approximately 35% of investment initiatives are directed toward advanced manufacturing processes, improved radioactive material handling systems, and development of reliable supply networks that support healthcare providers. Companies are prioritizing modernization of production facilities, automation of quality monitoring procedures, and enhancement of logistics infrastructure to ensure consistent availability of therapeutic capsules for hospitals and nuclear medicine centers.

Future opportunities are emerging through expansion of nuclear medicine infrastructure, increasing demand for targeted thyroid therapies, and rising healthcare investments in developing regions. Around 31% of future market opportunities are associated with improving treatment accessibility, establishing specialized therapy centers, and developing advanced solutions that support personalized radioactive iodine treatment approaches. Growing investments in radiopharmaceutical research, collaborations between healthcare institutions and manufacturers, and expansion of regional production capabilities are expected to create additional growth opportunities for market participants.

New Product Development

New product development activities in the Sodium Iodide 131 Therapeutic Capsule Market are focused on improving capsule safety, dosage consistency, and therapeutic efficiency. Approximately 34% of innovation efforts are directed toward enhancing product design, improving manufacturing accuracy, and developing solutions that support better treatment outcomes for thyroid cancer and hyperthyroidism patients. Manufacturers are working on improving capsule reliability, reducing handling risks, and optimizing radioactive iodine formulations to meet the evolving requirements of nuclear medicine professionals.

Manufacturers are also focusing on improving distribution efficiency, radiation safety technologies, and healthcare integration capabilities. Around 30% of new development programs are associated with improving supply reliability, strengthening quality assurance processes, and creating advanced therapeutic solutions suitable for expanding nuclear medicine applications. New initiatives include improved packaging systems, enhanced tracking technologies, and better integration with hospital treatment workflows to support safe and efficient radioactive therapy delivery.

Five Recent Developments

• January 2025 – Manufacturing Capacity Enhancement: Leading isotope producers expanded production capabilities, with approximately 26% of operational improvements focused on increasing therapeutic capsule availability and strengthening supply reliability.
• April 2025 – Radiopharmaceutical Technology Upgrade: Companies introduced improved production technologies, with around 28% of development activities focused on enhancing radioactive iodine preparation accuracy and quality control systems.
• August 2025 – Nuclear Medicine Partnership Expansion: Industry participants strengthened healthcare collaborations, with approximately 23% of partnership activities aimed at improving access to targeted thyroid treatment solutions.
• February 2026 – Product Quality Improvement Initiative: Manufacturers enhanced capsule production standards, with around 32% of quality programs focused on improving safety, consistency, and therapeutic performance.
• June 2026 – Global Distribution Network Expansion: Market participants expanded international supply capabilities, with approximately 29% of logistics improvements directed toward faster and more reliable therapeutic product delivery.

Report Coverage

The Sodium Iodide 131 Therapeutic Capsule Market report provides comprehensive analysis of industry trends, market dynamics, segmentation, regional developments, competitive landscape, investment activities, and future growth opportunities. The study evaluates major product categories including 37-7400 MBq/ Capsule and 7400MBq-/ Capsule while analyzing key applications such as Thyroid Cancer Treatment and Hyperthyroidism Treatment.

The report examines market performance across North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World regions while analyzing strategies of leading companies including ANSTO, PDRadiopharma Inc., China Isotope & Radiation Corporation (CIRC), International Isotopes Inc, Curium Pharma, Jubilant Pharmova, POLATOM–NCBJ, NTP Radioisotopes, and Isotope JSC (Rosatom). Approximately 9 major companies are reviewed to understand competitive positioning, manufacturing strategies, product development activities, and technological advancements influencing the future of Sodium Iodide 131 Therapeutic Capsule applications.